UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: September, 2005
Commission File Number: 000-50393
NEUROCHEM INC.
275 Armand-Frappier Boulevard
Laval, Quebec
H7V 4A7
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40 F. Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
September 27, 2005
By: /s/ Dr. Lise Herbert
-----------------------------
Dr. Lise Hebert
Vice President,
Corporate Communications
NEUROCHEM INC.
[LOGO NEUROCHEM] 275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V 4A7
- --------------------------------------------------------------------------------
FOR FURTHER INFORMATION, PLEASE CONTACT:
Lise Hebert, Ph.D. Tel: (450) 680-4570
Vice President, Corporate Communications lhebert@neurochem.com
NEUROCHEM TO PRESENT AT
2005 UBS GLOBAL LIFE SCIENCES CONFERENCE
IN NEW YORK CITY
MONTREAL, CANADA, SEPTEMBER 26, 2005 - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
announced today that on Wednesday, September 28, 2005, Dr. Francesco Bellini,
Neurochem's Chairman, President and CEO, will present the Company's overall
strategy and progress to date at the 2005 UBS Global Life Sciences Conference,
which will be held at the Grand Hyatt Hotel, in New York City. The presentation
will take place at 9:00 A.M. ET, in Ballroom B/Broadway.
Access to the audio portion of the conference is available via www.ibb.ubs.com.
Audio transmission of the presentation will be available live and by replay. The
replay presentation will begin 3 hours after the actual presentation time and
will be available until October 29, 2005.
The corporate presentation, as well as the audio webcast, will be available on
the Company's Web site at http://www.neurochem.com/Investor.htm#Presentation.
The webcast will be available for 30 days following the presentation.
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics for neurological disorders. The Company's pipeline of proprietary,
disease-modifying oral products addresses critical unmet medical needs.
1,3-propanedisulfonate (1,3PDS; Fibrillex(TM)) is designated as an orphan drug,
a Fast Track product candidate and is also part of an FDA Continuous Marketing
Applications Pilot 2 program. The Phase II/III clinical trial of Fibrillex(TM)
for the treatment of AA Amyloidosis was concluded in April 2005. The Company is
in the process of submitting a New Drug Application (NDA) for Fibrillex(TM) that
the FDA has agreed to
file and review. 3-amino-1-propanesulfonic acid (3APS; Alzhemed(TM)), for the
treatment of Alzheimer's disease, is in a North American as well as European
Phase III clinical trial and 3APS (Cerebril(TM)), for the prevention of
Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase
IIa clinical trial.
TO CONTACT NEUROCHEM
For additional information on Neurochem and its drug development programs,
please call the North American toll-free number 1 (877) 680-4500 or visit our
Web Site at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond Neurochem's control. Such risks
include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory
environment in the jurisdictions in which Neurochem does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation, as well as other risks disclosed in public filings of
Neurochem. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance, if any, on the forward-looking statements
included in this news release. These statements speak only as of the date made
and Neurochem is under no obligation and disavows any intention to update or
revise such statements as a result of any event, circumstances or otherwise.
Please see the Annual Information Form for further risk factors that might
affect the Company and its business.